CRISPR Therapeutics (CRSP) Short Interest Ratio & Short Volume → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free CRSP Stock Alerts $56.22 +0.55 (+0.99%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media CRISPR Therapeutics Short Interest DataCurrent Short Volume14,590,000 sharesPrevious Short Volume14,740,000 sharesChange Vs. Previous Month-1.02%Dollar Volume Sold Short$773.12 millionShort Interest Ratio / Days to Cover8.5Last Record DateApril 30, 2024Outstanding Shares84,918,000 sharesPercentage of Shares Shorted17.18%Today's Trading Volume1,083,032 sharesAverage Trading Volume1,420,640 sharesToday's Volume Vs. Average76% Short Selling CRISPR Therapeutics ? Sign up to receive the latest short interest report for CRISPR Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCRSP Short Interest Over TimeCRSP Days to Cover Over TimeCRSP Percentage of Float Shorted Over Time Ad Porter & CompanyGuard Against the Coming Financial UpheavalAmerica’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. CRISPR Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202414,590,000 shares $773.12 million -1.0%N/A8.5 $52.99 4/15/202414,740,000 shares $865.53 million -0.1%N/A8.5 $58.72 3/31/202414,760,000 shares $1.01 billion +0.3%N/A7.9 $68.16 3/15/202414,720,000 shares $1.07 billion -2.3%N/A7.4 $72.95 2/29/202415,060,000 shares $1.27 billion +1.3%N/A5.8 $84.22 2/15/202414,870,000 shares $1.26 billion -5.5%N/A5.5 $84.48 Get the Latest News and Ratings for CRSP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202415,740,000 shares $990.83 million -7.6%N/A5.6 $62.95 1/15/202417,040,000 shares $1.09 billion +4.9%N/A5.8 $64.25 12/31/202316,250,000 shares $1.02 billion -6.2%N/A5.9 $62.60 12/15/202317,330,000 shares $1.08 billion +8.8%N/A6.6 $62.08 11/30/202315,930,000 shares $1.06 billion -2.7%N/A7 $66.73 11/15/202316,370,000 shares $920.49 million +17.9%N/A9.6 $56.23 10/31/202313,890,000 shares $540.74 million +2.5%N/A10.9 $38.93 10/15/202313,550,000 shares $600.40 million +3.9%N/A13.3 $44.31 9/30/202313,040,000 shares $591.89 million -5.4%N/A13.4 $45.39 9/15/202313,790,000 shares $697.50 million -2.1%N/A14.6 $50.58 8/31/202314,080,000 shares $704.14 million +5.0%N/A13.7 $50.01 8/15/202313,410,000 shares $652.80 million +10.7%N/A11.9 $48.68 7/31/202312,110,000 shares $694.27 million -1.6%N/A9.5 $57.33 7/15/202312,310,000 shares $700.56 million -2.1%N/A9.8 $56.91 6/30/202312,570,000 shares $705.68 million +0.8%16.6%9.2 $56.14 6/15/202312,470,000 shares $734.98 million +2.3%16.5%9 $58.94 5/31/202312,190,000 shares $780.65 million -1.9%16.1%9.1 $64.04 5/15/202312,430,000 shares $819.76 million -5.8%16.4%9.5 $65.95 4/30/202313,200,000 shares $646.01 million +1.9%17.5%11.1 $48.94 4/15/202312,950,000 shares $651.51 million +2.0%17.2%11.3 $50.31 3/31/202312,700,000 shares $574.42 million +4.3%16.9%12.2 $45.23 3/15/202312,180,000 shares $547.13 million +9.0%16.2%11.3 $44.92 2/28/202311,170,000 shares $550.90 million +9.0%14.8%10 $49.32 2/15/202310,250,000 shares $534.74 million +2.7%13.7%9.4 $52.17 1/31/20239,980,000 shares $509.18 million +1.0%13.3%9.2 $51.02 1/15/20239,880,000 shares $493.41 million -5.7%13.2%9.1 $49.94 12/30/202210,480,000 shares $426.01 million +12.2%14.0%9.9 $40.65 12/15/20229,340,000 shares $443.65 million -16.2%12.4%8.8 $47.50 11/30/202211,140,000 shares $610.36 million -4.3%14.8%10.6 $54.79 11/15/202211,640,000 shares $710.16 million -7.3%15.5%10.8 $61.01 10/31/202212,550,000 shares $656.87 million +6.7%16.7%11.4 $52.34 10/15/202211,760,000 shares $635.86 million +1.7%15.7%10.4 $54.07 9/30/202211,560,000 shares $755.45 million +5.8%16.1%9.1 $65.35 9/15/202210,930,000 shares $819.86 million +0.5%15.3%7.5 $75.01Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. CRSP Short Interest - Frequently Asked Questions What is CRISPR Therapeutics' current short interest? Short interest is the volume of CRISPR Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 14,590,000 shares of CRSP short. Learn More on CRISPR Therapeutics' current short interest. What is a good short interest ratio for CRISPR Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRSP shares currently have a short interest ratio of 8.0. Learn More on CRISPR Therapeutics's short interest ratio. Which institutional investors are shorting CRISPR Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CRISPR Therapeutics: Walleye Trading LLC, Ikarian Capital LLC, Jane Street Group LLC, Yiheng Capital Management L.P., Torno Capital LLC, PEAK6 Investments LLC, Twin Tree Management LP, Concourse Financial Group Securities Inc., Simplex Trading LLC, and IMC Chicago LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is CRISPR Therapeutics' short interest increasing or decreasing? CRISPR Therapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 14,590,000 shares, a decrease of 1.0% from the previous total of 14,740,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does CRISPR Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to CRISPR Therapeutics: Krystal Biotech, Inc. (9.07%), Immunovant, Inc. (14.80%), Halozyme Therapeutics, Inc. (6.69%), ImmunityBio, Inc. (40.08%), Revolution Medicines, Inc. (7.59%), Exelixis, Inc. (3.35%), SpringWorks Therapeutics, Inc. (13.51%), Iovance Biotherapeutics, Inc. (22.64%), Denali Therapeutics Inc. (8.16%), Immunocore Holdings plc (9.37%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short CRISPR Therapeutics stock? Short selling CRSP is an investing strategy that aims to generate trading profit from CRISPR Therapeutics as its price is falling. CRSP shares are trading up $0.55 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CRISPR Therapeutics? A short squeeze for CRISPR Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRSP, which in turn drives the price of the stock up even further. How often is CRISPR Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRSP, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Krystal Biotech Short Interest Immunovant Short Interest Halozyme Therapeutics Short Interest ImmunityBio Short Interest Revolution Medicines Short Interest Exelixis Short Interest SpringWorks Therapeutics Short Interest Iovance Biotherapeutics Short Interest Denali Therapeutics Short Interest Immunocore Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRSP) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDon’t expose yourself to stocks during the weekDTIRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHas Trump Finally Gone Too Far?Insiders ExposedDoes this make you sick?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow this is some devastating newsWealthPress